[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hepatitis B immune globulin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Belimumab.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ipilimumab.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Brentuximab vedotin.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hepatitis B immune globulin.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Hepatitis B immune globulin.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hepatitis B immune globulin.]
[L01FD02, pertuzumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Pertuzumab.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Raxibacumab.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Siltuximab.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ramucirumab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Vedolizumab.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Pembrolizumab.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Dulaglutide.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Blinatumomab.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Nivolumab.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Secukinumab.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Alirocumab.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Evolocumab.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Idarucizumab.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Asfotase alfa.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Mepolizumab.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Daratumumab.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Necitumumab.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Elotuzumab.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Tetanus immune globulin, human.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ixekizumab.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Reslizumab.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Obiltoxaximab.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Atezolizumab.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Bezlotoxumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Olaratumab.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Brodalumab.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Avelumab.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ocrelizumab.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Dupilumab.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Hepatitis B immune globulin.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Hepatitis B immune globulin.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Durvalumab.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Sarilumab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Guselkumab.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Hepatitis B immune globulin.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Inotuzumab ozogamicin.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Hepatitis B immune globulin.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Benralizumab.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Emicizumab.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ibalizumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Burosumab.]
[N02CD01, erenumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Erenumab.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Tildrakizumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Mogamulizumab.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Fremanezumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Galcanezumab.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Emapalumab.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Caplacizumab.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Romosozumab.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Risankizumab.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Polatuzumab vedotin.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Brolucizumab.]
[L01FD01, trastuzumab, The risk or severity of adverse effects can be increased when Trastuzumab is combined with Hepatitis B immune globulin.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Trastuzumab emtansine.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Trastuzumab deruxtecan.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Isatuximab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Eptinezumab.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Sacituzumab govitecan.]
[L04AA47, inebilizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Inebilizumab.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Belantamab mafodotin.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Hepatitis B immune globulin.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ansuvimab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Margetuximab.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hepatitis B immune globulin.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Loncastuximab tesirine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Amivantamab.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Sotrovimab.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Aducanumab.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Anifrolumab.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Tisotumab vedotin.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Tralokinumab.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Sutimlimab.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Spesolimab.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Tremelimumab.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ublituximab.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Panitumumab is combined with Hepatitis B immune globulin.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Bimekizumab.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Antilymphocyte immunoglobulin (horse).]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Hepatitis B immune globulin.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Hepatitis B immune globulin.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Hepatitis B immune globulin.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Hepatitis B immune globulin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the thrombogenic activities of Hepatitis B immune globulin.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Hepatitis B immune globulin.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Hepatitis B immune globulin.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Human Rho(D) immune globulin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Natalizumab is combined with Hepatitis B immune globulin.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Hepatitis B immune globulin.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Hepatitis B immune globulin.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Human varicella-zoster immune globulin.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Hepatitis B immune globulin.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Hepatitis B immune globulin.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Hepatitis B immune globulin.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Hepatitis B immune globulin.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Hepatitis B immune globulin.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Hepatitis B immune globulin.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Hepatitis B immune globulin.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Ranibizumab is combined with Hepatitis B immune globulin.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Tocilizumab.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ofatumumab.]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Edrecolomab.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Golimumab.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Hepatitis B immune globulin.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ustekinumab.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Canakinumab.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Denosumab.]
